Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model

Multiple Sclerosis

Volumn 10, Issue 2, 2004, Pages 158-164

  Ni, Xiang ^a   Geller, Ellen B ^a   Eppihimer, Michael J ^c   Eisenstein, Toby K ^b   Adler, Martin W ^a   Tuma, Ronald F ^a  

^a TEMPLE UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

Author keywords

Cannabinoid; Cannabinoid receptor 1 and 2; Experimental autoimmune encephalomyelitis; Leukocyte endothelial interaction; Multiple sclerosis

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; KETAMINE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PERTUSSIS TOXIN; RIMONABANT; XYLAZINE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; BRAIN; CONTROLLED STUDY; DRUG MECHANISM; DRUG SELECTIVITY; FEMALE; IMPLANTATION; IN VIVO STUDY; LEUKOCYTE ADHERENCE; LEUKOCYTE ROLLING; MICROSCOPY; MOLECULAR INTERACTION; MOUSE STRAIN; NONHUMAN; VASCULAR ENDOTHELIUM;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CELL ADHESION; CELL COMMUNICATION; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; FEMALE; LEUKOCYTE ROLLING; LEUKOCYTES; MICE; MICE, INBRED C57BL; MORPHOLINES; MULTIPLE SCLEROSIS; NAPHTHALENES; PARALYSIS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 16544377251     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1009oa     Document Type: Article

References (50)

1. Noseworthy JH. Management of multiple sclerosis: current trials and future options. Curr Opin Neurol 2003; 16: 289-97.
2. Ali H, Haribabu B, Richardson RM, Snyderman R. Mechanisms of inflammation and leukocyte activation. Med Clin North Am 1997; 81: 1-28.
3. Beekhuizen H, van de Gevel JS. Endothelial cell adhesion molecules in inflammation and postischemic reperfusion injury. Transplant Proc 1998; 30: 4251-56.
4. Cavenagh JD, Cahill MR, Kelsey SM. Adhesion molecules in clinical medicine. Crit Rev Clin Lab Sci 1998; 35: 415-59.
5. Panes J, Granger DN. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology 1998; 114: 1066-90.
6. Kerfoot S, Kubes P. Overlapping roles of P-selectin and alpha 4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis. J Immunol 2002; 169: 1000-1006.
7. Pertwee R. Cannabinoids and multiple sclerosis. Pharmacol Ther 2002; 95: 165-74.
8. Fahim MA, El-Sabban F. Hyperthermia induces ultrastructural changes in mouse pial microvessels. Anat Rec 1995; 242: 77-82.
9. Yong T, Linthicum DS. Microvascular leakage in mouse pial venules induced by bradykinin. Brain Inj 1996; 10: 385-93.
10. Jallo J, Saetzler R, Mishke C, Young WF, Vasthare U, Tuma RF. A chronic model to simultaneously measure intracranial pressure, cerebral blood flow, and study the pial microvasculature. J Neurosci Methods 1997; 75: 155-60.
11. Sanna V, Di Giacomo A, La Cava A, Lechler R, Fontana S, Zappacosta S et al. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J Clin Invest 2003; 111: 241-50.
12. Becher B, Durell B, Noelle R. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest 2002; 110: 493-97.
13. Chitnis T, Najafian N, Benou C, Salama A, Grusby M, Sayegh M et al. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J Clin Invest 2001; 108: 739-47.
14. Ni X, Gritman K, Eisenstein T, Adler M, Arfors K, Tuma R. Morphine attenuates leukocyte/endothelial interactions. Microvasc Res 1999; 60: 121-30.
15. Saetzler RK, Jallo J, Lehr HA, Philips CM, Vasthare U, Arfors KE et al. Intravital fluorescence microscopy: impact of light-induced phototoxicity on adhesion of fluorescently labeled leukocytes. J Histochem Cytochem 1997; 45: 505-13.
16. Kanwar J, Kanwar R, Wang DGW, Krissansen G. Prevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of disease progression. Immunol Cell Biol 2000; 78: 641.
17. Kawachi S, Jennings S, Panes J, Cockrell A, Laroux FS, Gray L et al. Cytokine and endothelial cell adhesion molecule expression in interleukin-10-deficient. Am J Physiol Gastrointest Liver Physiol 2000; 278; G734-43.
18. Schiffenbauer J, Butfiloski E, Hanley G, Sobel E, Streit W, Lazarovits A. Prevention of experimental allergic encephalomyelitis by an antibody to CD45RB. Cell Immunol 1998; 190: 173.
19. Theien B, Vanderlugt C, Eagar T, Nickerson-Nutter C, Nazareno R, Kuchroo V et al. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest 2001; 107: 995-1006.
20. Hemmer B, Cepok S, Nessler S, Sommer N. Pathogenesis of multiple sclerosis: an update on immunology. Curr Opin Neurol 2002; 15: 227-31.
21. Brundula V, Rewcastle N, Metz LM, Bernard C, Yong V. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002; 125: 1297-308.
22. Noseworthy J, Lucchinetti C, Rodriguez M, Weinshenker B. Multiple sclerosis. N Engl J Med 2000; 343: 938-52.
23. Malik AB. Endothelial cell interactions and integrins. New Horiz 93; 1: 37-51.
24. Wahl SM, Feldman GM, McCarthy JB. Regulation of leukocyte adhesion and signaling in inflammation and disease. J Leukoc Biol 1996; 59: 789-96.
25. Mendel I, Kerlero de Rosbo N, Ben-Nun A. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur J Immunol 1995; 25: 1951-59.
26. Graesser D, Solowiej A, Bruckner M, Osterweil E, Juedes A, Davis S et al. Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice. J Clin Invest 2002; 109: 383-92.
27. van der Laan L, van der Goes A, Wauben M, Ruuls S, Dopp E, De Groot C et al. Beneficial effect of modified peptide inhibitor of alpha4 integrins on experimental allergic encephalomyelitis in Lewis rats. J Neurosci Res 2002; 67: 191-99.
28. Shao H, Sun S, Kaplan H, Sun D. Induction of autoimmune encephalomyelitis and uveitis in B6 and (B6 x SJL) mice by peptides derived from myelin/oligodendrocyte glycoprotein. J Neuroimmunol 2002; 132: 117-22.
29. Bar-Or A, Oliveira EM, Anderson DE, Hafler DA. Molecular pathogenesis of multiple sclerosis. J Neuroimmunol 1999; 100: 252-9.
30. Kallmann B, Hummel V, Lindenlaub T, Ruprecht K, Toyka K, Rieckmann P. Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. Brain 2000; 123: 687-97.
31. Hori J, Isobe M, Yamagami S, Mizuochi T, Tsuru T. Specific immunosuppression of corneal allograft rejection by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice. Exp Eye Res 1997; 65: 898-98.
32. Brocke S, Piercy C, Steinman L, Weissman IL, Veromaa T. Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc Natl Acad Sci USA 1999; 96: 6896-901.
33. Carrithers MV, Kang, SJ. Janeway CA Jr. Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment. Brain 2000; 123: 1092-101.
34. Berdyshev E. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 2000; 108: 169-90.
35. Klein T, Newton C, Friedman H. Cannabinoid receptors and immunity. Immunol Today 1998; 19: 373-81.
36. Watson S, Benson JJ, Joy JE. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry 2000; 57: 547-52.
37. Buckley N, McCoym K, Mezeym E, Bonner T, Zimmerm A, Felderm C et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 2000; 396: 141-49.
38. Smith P. Cannabinoids in the treatment of pain and spasticity in multiple sclerosis. Curr Opin Investig Drugs 2000; 3: 859-64.
39. Lyman WD, Sonnett JR, Brosnan CF, Elkin R, Bornstein MB. Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 1989; 23: 73-81.
40. Wirguin IM, Breuer R, Schezen A, Weidenfeld E, Brenner T. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 1994; 28: 209-14.
41. Baker DP, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 4: 4.
42. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 1997; 100: 1538-46.
43. Maccarrone M, Bari M, Lorenzon T, Bisogno T, Di Marzo V et al. Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J Biol Chem 2002; 275: 13484-92.
44. Ross R, Brockie H, Pertwee R. Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. Eur J Pharmacol 2000; 401: 121-30.
45. Sicher S, Vazquez M, Lu C. Inhibition of macrophage Ia expression by nitric oxide. J Immunol 1994; 153: 1293-304.
46. Albina J, Henry W. Suppression of lymphocyte proliferation through the nitric oxide synthesizing pathway. J Surg Res 1991; 50: 403-407.
47. Kubes P, Suzuki M, Granger D. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991; 88: 4651-54.
48. MacMicking J, Willenborg D, Weidemann M, Rockett K, Cowden W. Elevated secretion of reactive nitrogen and oxygen intermediates by inflammatory leukocyte in hyperacutes experimental autoimmune encephalomyelitis: enhancement by the soluble products of encephalitogenic T cells. J Exp Med 1992; 176: 303-307.
49. Cross A, Misko T, Lin R, Hickey W, Trotter J, Tilton R. Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J Clin Invest 1994; 93: 2684-90.
50. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 1997; 120: 865-916. fs